Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations.

88 A subsequent MRI analysis of CONFIRM also showed that DMF BID and TID produced significant and consistent reductions versus placebo of lesion volumes, but reductions in brain atrophy and magnetization-transfer ratio changes did not reach statistical significance. 89 An integrated analysis of the two pivotal Phase III trials showed that at 2 years, DMF 240 mg BID and TID significantly reduced the ARR and the risks of relapses, with 12-week and 24-week confirmed disability worsening in respect to placebo. 90 Although the efficacy of DMF is generally consiste

also in 111,027 other papers